ArticleJournal of inflammation research2026
Intestinal Stenosis Related to Immune Checkpoint Inhibitors Caused by Sintilimab: A Case Report.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) as an immunotherapy have significantly prolonged the overall survival (OS) and progression-free survival (PFS) of patients with various advanced cancers, and have significantly increased the objective response rate. However, excessive activation of the immune system may attack normal organs, triggering a series of immune-related adverse reactions. Among them, due to the relatively high incidence of immune-mediated colitis (IMC), it is particularly worthy of attention. Xindili Antibody is a fully human immunoglobulin G4 monoclonal antibody that targets the programmed cell death receptor 1 (PD-1) pathway. It is of great significance in cancer immunotherapy and has shown good anti-tumor effects in various malignant tumors. Here, we report a case of a 64-year-old male with colorectal cancer and lung metastasis. After using Sintilimab, the patient developed inflammatory intestinal obstruction. The colonic stenosis caused by immune checkpoint inhibitors may be the result of the combined effects of chronic immune inflammation, microbial flora imbalance, and disrupted tissue repair. This case report emphasizes the importance of early identification and appropriate intervention to prevent the permanent interruption of immune checkpoint inhibitor treatment and the prevention of colitis complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.